COMMUNIQUÉS West-GlobeNewswire

NEXGEL Appoints Ian Blackman as Chief Financial Officer
27/04/2026
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company [...]
Opus Genetics to Participate in Leading Medical Conferences in May 2026
27/04/2026
RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and [...]
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
27/04/2026
Definitive Agreement Targeted for Execution by June 2026 TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company [...]
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
27/04/2026
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no [...]
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
27/04/2026
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04’s role in providing a treatment option for patients where existing treatments inadequately [...]
KFSH Joins Milken Institute Global Conference 2026 in Beverly Hills, California, as a Silver Sponsor
27/04/2026
BEVERLY HILLS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will participate as a Silver Sponsor at the Milken Institute Global Conference 2026, taking place in [...]
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
27/04/2026
DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
27/04/2026
Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari’s global intellectual property across all major [...]
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
27/04/2026
Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis Once-daily ZORYVE cream was well tolerated with a [...]
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
27/04/2026
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development VANCOUVER, Washington, April 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (" [...]
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
27/04/2026
Conference call and live webcast today at 4:30 PM Eastern Time SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, [...]
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
27/04/2026
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage [...]
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
27/04/2026
On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration’s final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of [...]
Backed by Goldman Sachs, Urgent Care Provider Xpress Wellness Appoints New Chief Operating Officer to Support Continued Growth
27/04/2026
New COO Joe Willey brings experience leading large-scale, people-first organizations to support expanding access to care across rural and suburban communities OKLAHOMA CITY, April 27, 2026 (GLOBE NEWSWIRE) -- Xpress [...]
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
27/04/2026
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in angioimmunoblastic T-cell [...]
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
27/04/2026
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term [...]
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
27/04/2026
Topline data is on track for anticipated readout in the summer of 2026 WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission [...]
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27/04/2026
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and [...]
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
27/04/2026
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today [...]

Pages